{"id":"W4380290922","doi":"10.1001/jamaneurol.2023.1625","title":"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis","year":2023,"lang":"en","type":"article","venue":"JAMA Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; EMD Serono; Trish Multiple Sclerosis Research Foundation; Dementia Australia; Teva Pharmaceutical Industries; Royal Melbourne Hospital Neuroscience Foundation; Alexion Pharmaceuticals; Multiple Sclerosis Australia; Shionogi; Sanofi; Sanofi Genzyme; University of Melbourne; Atara Biotherapeutics; Medical Research Council; Biogen; Bristol-Myers Squibb","keywords":"Ocrelizumab; Relapsing remitting; Multiple sclerosis; Rituximab; Medicine; Dermatology; Internal medicine; Immunology; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007570881,0.0002386218,0.0006538355,0.0006561728,0.0001723443,0.00003432602,0.0002248369,0.0003277311,0.0001251337],"category_scores_gemma":[0.006891288,0.0002243692,0.0001382623,0.001167596,0.0002364536,0.0001249447,0.0004445112,0.001299448,0.0008887547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006937285,"about_ca_system_score_gemma":0.00007826405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002860371,"about_ca_topic_score_gemma":0.0001789651,"domain_scores_codex":[0.9970848,0.0002884117,0.0005028048,0.0006733385,0.0004658738,0.0009847495],"domain_scores_gemma":[0.9976782,0.00139262,0.00009330646,0.0005213954,0.0001263523,0.0001880888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004629113,0.0006857239,0.8072226,0.0002718695,0.0001118741,0.001101559,0.001246896,0.0002405784,0.06135861,0.00008777529,0.0527069,0.07033651],"study_design_scores_gemma":[0.0111464,0.0006396835,0.9593884,0.0001310892,0.00001470688,0.00005302266,0.00008427252,0.01443909,0.0009760794,0.00005306107,0.01290515,0.0001690636],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9664788,0.0001923543,0.00001312854,0.02891093,0.0003752389,0.0005495905,0.00001297882,0.0003931723,0.00307383],"genre_scores_gemma":[0.9945649,0.001203319,0.0002678895,0.003006206,0.0003633423,0.0001288052,0.00002905147,0.0000614167,0.0003750695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1521658,"threshold_uncertainty_score":0.9998892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08027053078908819,"score_gpt":0.308107479822876,"score_spread":0.2278369490337878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}